Shares of Irhythm Technologies Inc (NASDAQ:IRTC) have received an average rating of “Hold” from the eight analysts that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $67.50.
A number of analysts have recently issued reports on IRTC shares. Canaccord Genuity lifted their target price on Irhythm Technologies from $55.00 to $59.00 and gave the stock a “buy” rating in a research report on Thursday, November 2nd. Morgan Stanley lifted their target price on Irhythm Technologies from $50.00 to $65.00 and gave the stock an “overweight” rating in a research report on Friday, November 3rd. Dougherty & Co started coverage on Irhythm Technologies in a research report on Friday, December 1st. They set a “neutral” rating on the stock. Royal Bank of Canada started coverage on Irhythm Technologies in a research report on Monday, December 4th. They set an “outperform” rating and a $79.00 target price on the stock. Finally, BidaskClub lowered Irhythm Technologies from a “hold” rating to a “sell” rating in a research report on Thursday, December 14th.
Shares of Irhythm Technologies (NASDAQ IRTC) traded up $1.76 during midday trading on Wednesday, hitting $62.61. The stock had a trading volume of 436,143 shares, compared to its average volume of 230,952. Irhythm Technologies has a twelve month low of $32.10 and a twelve month high of $66.20. The stock has a market capitalization of $1,438.87, a price-to-earnings ratio of -48.16 and a beta of 1.56. The company has a debt-to-equity ratio of 0.38, a quick ratio of 7.57 and a current ratio of 7.65.
In related news, CFO Matthew C. Garrett sold 42,910 shares of Irhythm Technologies stock in a transaction dated Friday, January 5th. The stock was sold at an average price of $59.17, for a total value of $2,538,984.70. Following the completion of the transaction, the chief financial officer now directly owns 36,085 shares in the company, valued at $2,135,149.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Matthew C. Garrett sold 1,193 shares of Irhythm Technologies stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $55.00, for a total value of $65,615.00. The disclosure for this sale can be found here. Insiders sold 251,533 shares of company stock valued at $13,500,006 over the last quarter. Insiders own 23.30% of the company’s stock.
A number of large investors have recently bought and sold shares of the stock. BlackRock Inc. grew its stake in Irhythm Technologies by 8.1% in the fourth quarter. BlackRock Inc. now owns 1,604,250 shares of the company’s stock worth $89,917,000 after purchasing an additional 120,352 shares in the last quarter. Alliancebernstein L.P. grew its stake in Irhythm Technologies by 1.3% in the fourth quarter. Alliancebernstein L.P. now owns 1,016,126 shares of the company’s stock worth $56,954,000 after purchasing an additional 13,236 shares in the last quarter. Redmile Group LLC grew its stake in Irhythm Technologies by 47.6% in the fourth quarter. Redmile Group LLC now owns 814,574 shares of the company’s stock worth $45,657,000 after purchasing an additional 262,533 shares in the last quarter. Bank of New York Mellon Corp grew its stake in Irhythm Technologies by 2.6% in the fourth quarter. Bank of New York Mellon Corp now owns 756,700 shares of the company’s stock worth $42,413,000 after purchasing an additional 19,429 shares in the last quarter. Finally, Wells Fargo & Company MN grew its stake in Irhythm Technologies by 67.0% in the third quarter. Wells Fargo & Company MN now owns 609,187 shares of the company’s stock worth $31,604,000 after purchasing an additional 244,411 shares in the last quarter. Institutional investors and hedge funds own 99.18% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Irhythm Technologies Inc (IRTC) Receives Consensus Rating of “Hold” from Analysts” was first posted by Week Herald and is owned by of Week Herald. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://weekherald.com/2018/03/14/irhythm-technologies-inc-irtc-receives-consensus-rating-of-hold-from-analysts.html.
About Irhythm Technologies
iRhythm Technologies, Inc is a United States-based digital health company. The Company develops and commercializes solutions that integrate biosensor technology, patient data, analytics and medical expertise. The Company offers flagship solution, the ZIO Service. Its ZIO Service consists of the ZIO XT Patch, algorithms and the ZIO Report.
Receive News & Ratings for Irhythm Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Irhythm Technologies and related companies with MarketBeat.com's FREE daily email newsletter.